A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature. (2022)

Peer-Reviewed Study · Chain G; Kalia M; Kestenbaum K; Pappas L; Sechser-Perl A; Campino GA; Zaghloul N · February 2, 2022

Chain G et al., 2022-02-02: Case report and literature review of methylene blue used repeatedly for seven months to treat prolonged ifosfamide encephalopathy in an 11-year-old, recording the standard pharmacology: inhibition of chloroacetaldehyde formation, onset within 30 minutes, effect lasting up to three days.

MB acts to inhibit Chloroacetaldehyde formation and has been described as a therapy and prophylaxis for Ifosfamide-encephalopathy.

Chain G et al., 2022-02-02: Case report and literature review of methylene blue used repeatedly for seven months to treat prolonged ifosfamide encephalopathy in an 11-year-old, recording the standard pharmacology: inhibition of chloroacetaldehyde formation, onset within 30 minutes, effect lasting up to three days. C7 Chain 2022. Study type: single case report with literature review. N=1 (11-year-old girl with a non-germinomatous germ cell tumour). Country: USA. Dose/route/schedule of methylene blue: not stated in the abstract. Funder: not stated in the record. Conflicts: 'The authors declare that they have no competing interests.' Comparator: none (uncontrolled). Establishes the clinical use exists and is documented; it is not evidence of chemosensitisation or radioprotection. Also filed as MTI-64, MTK-37 (claims C6, C7, C8). Study type: case report.